Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of brexucabtagene autoleucel (KTE-X19) in relapsed/refractory chronic lymphocytic leukemia and relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2022-05-10